This October, don’t just wear pink—take action. Support MiraKind’s annual run/walk fundraiser to advance groundbreaking genetic research that’s changing how we understand, prevent, and treat cancer. Team MiraKind Is On the Move!…
Read More ➝
A new clinical trial published in the New England Journal of Medicine may change how some breast cancer patients are treated with radiation after chemotherapy and surgery. We spoke with Dr. Terry…
Read More ➝
We recently attended the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting—one of the world’s largest gatherings dedicated to advancing cancer care. This year’s event showcased a wave of innovation aimed…
Read More ➝
How can inherited genetic differences help predict who’s more likely to benefit from cancer treatment—or experience severe side effects? That question is at the heart of two new studies we recently shared…
Read More ➝
Happy Holidays! As we reflect on 2024, we’d like to share some of our achievements with you and express our gratitude to our patients and donors. These successes would not have been…
Read More ➝
Staying on top of health-related knowledge can be overwhelming. With constant advancements in science, it’s not always easy to keep track of new findings. Yet, it’s important to know which discoveries are…
Read More ➝
The number of women diagnosed with breast cancer who are later diagnosed with ovarian cancer is very low. However, the short answer is yes — having breast cancer does indicate you might…
Read More ➝
“People think it’s an old-age person’s disease. It’s like cancer was 25 years ago: You didn’t mention the C word. Cancer activists have done an excellent job of destigmatizing it, putting it…
Read More ➝
In November 2020, we announced that we had undertaken new research into other genetic variants that are connected to cancer. Specifically, ones that affect prostate cancer.1 Our research has produced a lot…
Read More ➝
The partners on the UCLA research team have made new discoveries about how genetic mutations can help doctors predict patient responses to cancer-fighting immunotherapy drugs. In the past, we have spoken a…
Read More ➝
Although much of the world has accepted that GWAS studies, which use an outdated technology looking at large amounts of data, have failed to find any functional mutations, this approach has twice…
Read More ➝
Disclaimer
Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.
